| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
Crow-Fukase syndrome is a rare multisystemic disorder characterized by polyneuropathy, effusion, renal dysfunction, and skin change. To investigate risk factors of recurrence after high dose chemotherapy with autologous stem-cell transplantation (HCT with ASCT), we studied clinical and laboratory profiles of 24 patients who underwent HCT with ASCT. Induction therapies prior to transplantation and lower VEGF levels were associated with lower risk for recurrence. Based on those findings we are planning a clinical trial to explore the efficacy of thalidomide as an induction therapy before transplantation.
|
